



EARNINGS RELEASE 2Q26



São Joaquim da Barra, August 12, 2026. Vittia S.A. (VITT3: BZ) ("Vittia" or "Company"), a Brazilian company specialized in biotechnology (biopesticides and inoculants) and special plant nutrition with solutions for several agricultural crops, announces its results for the second quarter of 2026 ("2Q26").

2Q26 Highlights



Cash generation from operating activities of **R\$ 102.6** million in 1H26, **42.3%** growth, resulting in net debt of **R\$ 96.4** million and leverage of **0.86x** Adjusted EBITDA

34.5% growth in the Biological and Natural Solutions line for the quarter and **5.7%** for the first half of 2026



Net revenue totaled **R\$ 114.0** million in 2Q26 (**+15.1%** vs. 2Q25) and **R\$ 236.0** million in 1H26 (**-0.4%** vs. 1H25)

Adjusted EBITDA was negative at **R\$ 16.8** million in 2Q26 (vs. **R\$ 20.8** million in 2Q25). In 1H26, it was negative at **R\$ 17.4** million (vs. **R\$ 13.9** million in 1H25)



The adjusted net result was negative at **R\$ 17.4** million in 2Q26 (vs. **R\$ 21.2** million in 2Q25) and **R\$ 23.3** million in 1H26 (vs. **R\$ 23.1** million in 1H25)

Payment of **R\$ 41.6** million between buyback and JCP in 1H26



Our Business

We operate in three product divisions, which are our reportable segments: (i) Soil Fertilizers; (ii) Foliar Fertilizers and Industrial Products; and (iii) Biological and Natural Solutions. These divisions have centralized management under the same corporate division, including the Board of Directors and Advisory Committees, Executive Board, Control and Operating Systems, and Technology and People, among others. We have specialized and capable teams to provide high-quality and unique products to continuously meet market demand and, with a focus on superior productivity and financial performance under the ESG matrix.

Message from Management

The second quarter of 2026 remained challenging for the Brazilian agribusiness sector. Farmers continued to face significant pressure on profitability due to a combination of depressed prices for key agricultural commodities, high production costs, and tighter financial conditions. In addition, concerns over the possibility of a stronger El Niño event during the 2026/27 summer crop season increased uncertainty among some farmers, particularly regarding weather conditions and their potential impact on yields.

Despite this environment, our consolidated net revenue increased by 15.1%, led by Biological and Natural Solutions, which grew by 34.5% in the quarter. As a result of this performance, adjusted EBITDA was R\$ 3.9 million higher than in the same period of the previous year. It is important to note that the second quarter traditionally falls within the off-season, with significantly lower sales volumes and, therefore, is less representative of the Company's full-year performance. In the year to date, net revenue remained broadly in line with the amount reported in 1H25, declining by 0.4%, while adjusted EBITDA was R\$ 3.5 million below the level recorded in 1H25.

Regarding receivables management, the first half of the year is the most significant period, and we once again delivered strong performance, particularly given the tighter credit environment and the recent rise in default rates observed in the agribusiness sector. Cash generation from operating activities reached R\$ 102.6 million in 1H26, a 42.3% increase compared to the same period of the previous year. As a result of this cash generation, net debt closed the semester at R\$ 96.4 million, a 16.3% reduction compared to 1H25. Leverage, measured by the net debt/adjusted EBITDA ratio, stood at 0.86x, remaining at a comfortable level. Vittia therefore continues to maintain a balanced capital structure that is appropriate for the current market environment and the execution of its strategies.

The Company continued to advance the initiatives introduced in late 2023 to streamline its organizational structure and control SG&A expenses. These measures contributed to preserving operating profitability and ensured that Vittia remained well positioned to continue investing in its strategic priorities.

In 2026, Vittia expanded its portfolio with four new product launches: **Guardium WP**, a biological insecticide and the Company's first solution to combine two complementary biological agents, featuring VIT CORE™ technology, which provides formulation enhancements designed to improve the protection, stability, and field performance of biological agents; **RizoForte**, designed to manage nematodes at different stages of their life cycle, particularly eggs and females, complementing No-Nema as part of an integrated nematode management strategy; **Aeron-N**, a new foliar application technology that supports biological nitrogen fixation processes and combines bioactive compounds, including biological nanoparticles, associated with plant vigor and physiological efficiency, also featuring VIT CORE™ technology; and **Fillus**, which combines essential macro and micronutrients to promote more balanced and efficient plant nutrition. These launches strengthen the Company's presence across different areas of crop management and reflect its strategy of continuously investing in Research, Development, and Innovation to provide farmers with enhanced technology and efficiency.

Over the last 12 months, Vittia returned R\$ 59.8 million to shareholders, comprising R\$ 37.0 million in interest on equity and R\$ 22.8 million through share repurchases. In 2026, through the end of July, share repurchases had already totaled approximately R\$ 17.6 million, demonstrating our confidence in the business.

During the quarter, we therefore continued to execute our strategy with discipline amid the current agribusiness environment, maintaining a prudent approach without losing sight of our strategic positioning and priority investments. We believe we are navigating this more challenging period for our industry efficiently, and we remain confident in the value of our business and prepared for a market recovery. These initiatives reinforce our new institutional positioning, "**Sou raiz, sou Vittia**," which reflects how we continue to build strong, long-term relationships based on trust, proximity, and the delivery of results for farmers and distribution channels.

For the second half of the year, we will continue to closely monitor credit conditions, agricultural commodity prices, the pace of negotiations for the 2026/27 crop season, developments in Brazil's electoral landscape, and the global geopolitical environment. We remain confident in the fundamentals of Brazilian agribusiness and in the growth potential of the biological technologies and specialty plant nutrition markets.

Economic and Financial Performance

In thousands of R\$	2Q26	2Q25	Chg. %	1H26	1H25	Chg. %
Net revenue	114,048	99,060	15.1%	235,962	236,880	(0.4%)
Cost of goods sold	(96,414)	(84,928)	13.5%	(183,112)	(180,707)	1.3%
Gross profit	17,634	14,132	24.8%	52,850	56,173	(5.9%)
Gross margin	15.5%	14.3%	1.2 p.p.	22.4%	23.7%	-1.3 p.p.
Operating expenses (i)	(43,613)	(43,941)	(0.7%)	(90,949)	(88,857)	2.4%
Adjusted EBITDA	(16,831)	(20,781)	(19.0%)	(17,418)	(13,919)	25.1%
Adjusted EBITDA margin	(14.8%)	(21.0%)	6.2 p.p.	(7.4%)	(5.9%)	-1.5 p.p.
Net financial result	(286)	(1,812)	(84.2%)	1,826	(1,304)	N/A
Income tax and social contribution	8,350	10,438	(20.0%)	11,876	10,847	9.5%
Net result	(17,915)	(21,182)	(15.4%)	(24,397)	(23,141)	5.4%
Net margin	(15.7%)	(21.4%)	5.7 p.p.	(10.3%)	(9.8%)	-0.5 p.p.
Adjusted Net result (iii)	(17,421)	(21,182)	(17.8%)	(23,323)	(23,141)	0.8%
Net margin	(15.3%)	(21.4%)	6.1 p.p.	(9.9%)	(9.8%)	-0.1 p.p.
Investments (fixed and intangible assets)	9,154	9,658	(5.2%)	15,340	14,970	2.5%

(i) The adjusted net result excludes the accounting impacts related to the late recovery of taxes, with both values considered net of the corresponding tax effects.

Operating income


Net operating income by segment

In thousands of R\$	2Q26	2Q25	Chg. %	1H26	1H25	Chg. %
Soil fertilizers	63,854	49,104	30.0%	90,036	78,292	15.0%
Foliar fertilizers and industrial products	18,388	26,306	(30.1%)	68,061	84,942	(19.9%)
Biological and natural solutions	31,806	23,650	34.5%	77,865	73,646	5.7%
Net revenue	114,048	99,060	15.1%	235,962	236,880	(0.4%)

Geographic breakdown

Vittia is present throughout Brazil and abroad, with revenue broken down as follows:

Breakdown of net revenue per region (R\$ million)



Gross profit and gross margin

In thousands of R\$	2Q26	2Q25	Chg. %	1H26	1H25	Chg. %
Soil fertilizers	2,803	2,392	17.2%	2,479	2,671	(7.2%)
Gross margin	4.4%	4.9%	-0.5 p.p.	2.8%	3.4%	-0.7 p.p.
Foliar fertilizers and industrial products	982	1,385	(29.1%)	12,338	11,770	4.8%
Gross margin	5.3%	5.3%	0.1 p.p.	18.1%	13.9%	4.3 p.p.
Biological and natural solutions	13,849	10,355	33.7%	38,033	41,732	(8.9%)
Gross margin	43.5%	43.8%	-0.2 p.p.	48.8%	56.7%	-7.8 p.p.
Gross profit	17,634	14,132	24.8%	52,850	56,173	(5.9%)
Gross margin	15.5%	14.3%	1.2 p.p.	22.4%	23.7%	-1.3 p.p.

Selling, general and administrative expenses (SG&A)

In thousands of R\$	2Q26	2Q25	Chg. %	1H26	1H25	Chg. %
Selling expenses	(14,786)	(15,244)	(3.0%)	(32,555)	(32,952)	(1.2%)
Provision for expected credit losses	(57)	(91)	(37.4%)	64	782	(91.8%)
General and administrative expenses	(30,491)	(29,185)	4.5%	(60,720)	(56,953)	6.6%
Other operating income (expenses)	1,721	579	197.2%	2,262	266	750.4%
Total SG&A expenses	(43,613)	(43,941)	(0.7%)	(90,949)	(88,857)	2.4%
Net revenue (%)	38.2%	44.4%	-6.1 p.p.	38.5%	37.5%	1.0 p.p.
(+) Late recovery of taxes (i)	749	-	N/A	1,628	-	N/A
Total SG&A excluding demobilization	(42,864)	(43,941)	(2.5%)	(89,321)	(88,857)	0.5%
Net revenue (%)	37.6%	44.4%	-6.8 p.p.	37.9%	37.5%	0.3 p.p.


(i) In 1H26, the company made a payment of fees resulting from the late recovery of taxes carried out in 2025. At that time, the company reviewed the tax records from April 2021 to March 2025 and identified late tax credits of R\$ 24,296 thousand relating to previous years.

SG&A totaled R\$ 89.3 million in 1H26, representing 37.9% of net revenue, a 0.3 p.p. increase compared to 1H25. This result reflects the cost rationalization and optimization initiatives implemented. The Company remains focused on its operational efficiency strategy, preserving its commercial capacity and sustaining its growth.


Adjusted EBITDA and Adjusted EBITDA Margin

The Company's adjusted EBITDA (excluding the adjustment to the present value of accounts receivable and non-recurring events) was negative by R\$ 17.4 million in 1H26, with an adjusted EBITDA margin of -7.4%, mainly due to the reduction in gross profit.

Adjusted EBITDA Performance (R\$ million)



Adjusted EBITDA margin performance



(1) SGA = General, administrative, other and non-recurring expenses / AFDA = Allowance for Doubtful Accounts / D&A = Depreciation and amortization / PVA = Present value adjustment

Reconciliation of net income and adjusted EBITDA

In thousands of R\$	2Q26	2Q25	Chg. %	1H26	1H25	Chg. %
Net result	(17,915)	(21,182)	(15.4%)	(24,397)	(23,141)	5.4%
(+) Income tax and social contribution	(8,350)	(10,438)	(20.0%)	(11,876)	(10,847)	9.5%
(+) Net financial income (loss)	286	1,812	(84.2%)	(1,826)	1,304	N/A
(+) Depreciation and amortization	6,053	6,433	(5.9%)	12,038	12,327	(2.3%)
EBITDA (i)	(19,926)	(23,376)	(14.8%)	(26,061)	(20,357)	28.0%
EBITDA Margin (i)	(17.5%)	(23.6%)	6.1 p.p.	(11.0%)	(8.6%)	-2.5 p.p.
(+) Present value adjustment – PVA	2,346	2,595	(9.6%)	7,015	6,438	9.0%
(+) Late recovery of taxes (iii)	749	-	N/A	1,628	-	N/A
Adjusted EBITDA (iii)	(16,831)	(20,781)	(19.0%)	(17,418)	(13,919)	25.1%
Adjusted EBITDA margin (i)	(14.8%)	(21.0%)	6.2 p.p.	(7.4%)	(5.9%)	-1.5 p.p.

(i): EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a non-accounting measure disclosed by the Company under CMV Instruction 527 of October 4, 2012 ("CMV Instruction 527"), reconciled with its financial statements, and consists of net income plus net financial result, income tax and social contribution expenses, and depreciation and amortization expenses and costs. The EBITDA margin is calculated by dividing EBITDA by the net operating income.

(ii) In 1H26, the company reviewed its tax records from April 2021 to March 2025 and identified overdue tax credits of R\$ 24,296 thousand relating to previous fiscal years.

Financial result

In thousands of R\$	2Q26	2Q25	Chg. %	1H26	1H25	Chg. %
Interest income and discounts	1,363	745	83.0%	3,325	1,237	168.8%
Present value adjustment (i)	5,770	5,711	1.0%	13,479	12,994	3.7%
Income from financial investments	2,001	1,413	41.6%	3,283	2,033	61.5%
Interest expenses	(9,279)	(5,807)	59.8%	(17,717)	(10,940)	61.9%
Discounts granted	(246)	(1,005)	(75.5%)	(1,173)	(1,205)	(2.7%)
Interest on right of use	(566)	(811)	(30.2%)	(1,213)	(1,529)	(20.7%)
Tax on financial transactions (IOF) and other	(114)	(222)	(48.6%)	(157)	(276)	(43.1%)
Exchange variation, net (ii)	(175)	3,606	N/A	749	8,739	(91.4%)
Gains (losses) with derivatives (ii)	959	(5,441)	N/A	1,250	(12,357)	N/A
Net financial result	(286)	(1,812)	(84.2%)	1,826	(1,304)	N/A

(i) The Present Value Adjustment (PVA), which includes our sales realized in the "Crop Period". In this procedure, the "Accounts Receivable" resulting from such sales are adjusted to their present value through discounts that consider pre-fixed embedded interest. To bring the "Accounts Receivable" to present value we use the average weighted funding cost. This practice has the following impact on our balance sheet and results: in the first moment, the PVA is deducted from our "Accounts Receivable" through an account that reduces the balance sheet, while gross revenue is also deducted at the same amount. With time, the amount deducted is accrued in the financial result under interest gains, reducing the value of the account that reduces the "Accounts Receivable". The monthly accrual is based on the rate used for the discount at the initial moment. Accordingly, upon payment, the value of "Accounts Receivable" is offset by fully debiting the cash account, and the total gross revenue arising from the sale in installments will be partially accrued as operating income upon delivery of the good and partially accrued every month as financial revenue until the payment is made.

(ii) To protect itself against risks from exchange rate variations, the Company uses derivative hedging instruments, mainly foreign exchange swaps and NDFs (non deliverable forwards). NDFs are generally used to manage currency exposure on balance sheets, avoiding or minimizing the


mismatch on accounts receivable, operating liabilities, and accounts payable that are denominated in dollars. Swaps are usually contracted through operations known as "4131 swaps". In these operations, the Company contracts a debt instrument in foreign currency (Dollar or Euro) with a financial institution, while contracting, at the same time, a swap operation, exchanging this obligation in foreign currency (long end for the Company) for yields based on the variation of Interbank Deposit Certificates – CDI, plus a spread (short end for the Company). These operations are carried out with the same counterparty and with the same amounts and maturity dates. Swaps are classified as fair value derivatives and their results are accounted for as gains (losses) on derivatives. Foreign currency debt is classified under loans and financing, with the result from the exchange variation and interest accounted for as financial expenses.

The net financial result in 2Q26 was negative by R\$ 0.3 million (-84.2% vs. 2Q25). In 1H26 the result was positive by R\$ 1.8 million (a reversal of the negative result of R\$ 1.3 million in 1H25). The variation in the result during the period is mainly due to the higher volume of interest income recognized on accounts receivable, as well as the increase in income from financial investments compared to the same period of the previous year.

Cash flow management and indebtedness

Cash flow management

Cash flow (R\$ million)



In Thousand of R\$	2Q26	2Q25	Chg. %	1H26	1H25	Chg. %
Cash Generation	55,883	45,911	21.7%	57,905	9,134	534.0%
Operating activities	117,202	118,356	(1.0%)	102,585	72,075	42.3%
Investments	(8,589)	(8,724)	(1.5%)	(14,320)	(13,622)	5.1%
Financing	(52,729)	(63,721)	(17.2%)	(30,359)	(49,319)	(38.4%)
Cash and cash equivalents at beginning of period	49,985	17,696	182.5%	47,963	54,473	(12.0%)
Cash and cash equivalents at end of period	105,868	63,607	66.4%	105,868	63,607	66.4%

The cash variation in 1H26 was positive by R\$ 57.9 million due to the amortization of financing, which reached R\$ 30.4 million (-38.4% vs. 1H25) and investments, which totaled R\$ 14.3 million (+5.1% vs. 1H25), offset by operating activities, which totaled R\$ 102.6 million (+42.3% vs. 1H25).

Indebtedness

The Company's gross debt reached R\$ 202.3 million in 1H26 (+13.1% vs. 1H25), while net debt registered R\$ 96.4 million (-16.3% vs. 1H25). The net debt/EBITDA ratio came to 0.86x.

In thousands of R\$, except %	1H26	1H25	Chg. %	2025	Chg. %
Loans and financing (current)	155,474	96,829	60.6%	124,930	24.4%
Loans and financing (non-current)	46,804	81,981	(42.9%)	48,627	(3.7%)
Gross debt	202,278	178,810	13.1%	173,557	16.5%
(-) Cash and cash equivalents	(105,868)	(63,607)	66.4%	(47,963)	120.7%
Net debt (i)	96,410	115,203	(16.3%)	125,594	(23.2%)
<i>LTM Adjusted EBITDA</i>	<i>111,725</i>	<i>130,614</i>	<i>(14.5%)</i>	<i>115,223</i>	<i>(3.0%)</i>
Net Debt/LTM EBITDA	0.86x	0.88x	-0.02x	1.09x	-0.23x

CAPEX and Research, Development and Innovation

Investments in CAPEX reached R\$ 15.3 million in 1H26 (+2.5% vs. 1H25). These CAPEX investments are primarily focused on operational improvements that can generate productivity gains and cost reductions, without focusing on large-scale projects. The CAPEX strategy seeks to adapt to the current moment of increased conservatism in agribusiness and rising interest rates in the country, seeking the efficient allocation of capital. The main investments planned for 2026 are:

Biologicals Plant:

Implementation of a new and modern filling unit for the formulated products line, designed to meet new demands and provide greater flexibility for new SKUs within the portfolio. An investment of R\$ 1.3 million was made in 1H26, out of a total of R\$ 9.6 million to be invested.

Inoculants Plant:

As part of operational improvement and modernization initiatives, the Company is expanding its fermentation area to support the entire inoculants product line, adding capacity of 1.92 million doses per month. An investment of R\$ 2.8 million was made in 1H26, out of a total of R\$ 5.9 million planned for 2026.

R&D Investments

The Company generates value through integrated teams, combining knowledge and experience from the areas of R&DI, Market Development and Regulatory Affairs. At the end of 2Q26, we had 53 R&DI professionals, 32 of whom were exclusively dedicated to this area.

In 1H26, the Company invested R\$ 12.5 million in research and development, which represents a 6.2% reduction compared to the same period of the previous year and corresponds to 5.3% of the Company's net revenue (-0.3 p.p. vs. 1H25). It is worth noting the seasonal nature of CAPEX investments, which does not indicate a reduction in the Company's R&D investments.

Research and Development Investments

In thousand of R\$	2Q26	2Q25	Chg. %	1H26	1H25	Chg. %
Biological products	4,597	5,307	(13.4%)	9,432	10,033	(6.0%)
Fertilizers	1,438	1,674	(14.1%)	3,085	3,310	(6.8%)
Total	6,036	6,981	(13.5%)	12,517	13,343	(6.2%)
Capex	324	91	254.6%	385	165	134.0%
Opex	5,712	6,889	(17.1%)	12,131	13,178	(7.9%)
Net revenue (%)	5.3%	7.0%	-1.7 p.p.	5.3%	5.6%	-0.3 p.p.

Key developments

With deep roots in research and innovation in the field, Vittia has become a national benchmark in biological crop protection and plant nutrition. Our commitment is to boost crop performance through sustainable, effective, and technological solutions, supported by ethics, knowledge, and experience.

We offer a complete and integrated portfolio that strengthens productivity and profitability while also contributing to the development of increasingly sustainable agriculture. During the quarter, the Company obtained 5 new recommendations for biological use/targets and 4 new Temporary Special Registrations.

During the period, Vittia also expanded its portfolio with four new product launches:

- **Guardium WP:** a biological insecticide and the Company's first solution to combine two complementary biological agents. It incorporates VIT CORE™ technology, which provides formulation enhancements designed to improve the protection, stability, and field performance of biological agents;
- **RizoForte:** a solution designed to manage nematodes at different stages of their life cycle, particularly eggs and females. It works in a complementary manner to No-Nema, expanding management options;
- **Aeron-N:** a new foliar application technology that supports biological nitrogen fixation processes and combines bioactive compounds, including biological nanoparticles, associated with plant vigor and physiological efficiency. It also incorporates VIT CORE™ technology; and
- **Fillus:** a solution that combines essential macro and micronutrients to promote more balanced and efficient plant nutrition.

These launches strengthen the Company's presence across biological crop protection, biostimulation, and plant nutrition, and reflect its strategy of continuously investing in Research, Development, and Innovation to provide farmers with enhanced technology, efficiency, and productivity.

Human Resources

We ended 2Q26 with 1,073 employees, compared to 1,169 in the previous quarter (-8.2% vs. 1Q26) and 1,158 in the same period of the previous year (-7.3% vs. 2Q25). All our employees, including those under temporary employment contracts, are directly hired by the Company under the Brazilian Consolidation of Labor Laws (CLT).

The Company maintains a close relationship with the unions that represent its employees. Collective agreements and conventions, as well as those negotiated directly, have a usual duration of 12 months. Vittia also complies with applicable labor laws and conditions established in collective bargaining agreements signed with labor unions, applying them equally to unionized and non-unionized employees.

Capital Markets

The shares of Vittia S.A. (B3: VITT3) have been traded since the IPO, on September 1, 2021, in the Novo Mercado segment of B3, the highest Corporate Governance level in the Brazilian stock market. The Company is also included in the IGC (Special Corporate Governance Stock Index), IGC-NM (Novo Mercado Corporate Governance Equity Index), and ITAG (Special Tag-Along Stock Index) indexes.

Share capital: Vittia's share capital was constituted, on 06/30/2026, by 157.6 million common shares (ON), of which 66.9% belonged to controlling shareholders, 2.6% to the Company's management, 30.0% were in free circulation on the market ("free float") and 0.5% were shares held in treasury.

Market cap: At the end of the quarter, VITT3 share was priced at R\$ 3.26, representing a market cap of R\$ 513.7 million, compared to R\$ 652.4 million at the end of the previous quarter, a decrease of 21.2% or R\$ 138.7 million.

Free-float Breakdown: At the end of 2Q26, the free float was distributed as follows: individual investors held 15.5% (vs. 15.0% in 1Q26), local institutional investors held 82.2% (vs. 83.1% in 1Q26), and foreign investors held 2.3% (vs. 1.9% in 1Q26).

Number of shareholders: At the end of the quarter, the Company had 4.4 thousand shareholders, compared to 4.7 thousand at the end of 1Q26, a decrease of 6.1%.

Average Daily Trading Volume ("ADTV"): The average daily trading volume was R\$ 1.0 million in 2Q26, compared to R\$ 1.1 million in the previous quarter, a decrease of R\$ 0.1 million or 11.5%.

Dividend distribution: By the end of 2Q26, the Company had paid R\$ 25.5 million in dividends, as JCP, paid on 01/06/2026 and 05/11/2026.

In the RCA held on July 14, 2025, the declaration of distribution of JCP calculated in the period from January to July 2025 was approved, in the gross amount of R\$ 20.8 million (R\$ 0.14040135117 per share) based on the shareholding position of July 18, 2025. The first installment, in the amount of R\$ 7.0 million (R\$ 0.04731352488 per share), was paid on August 13, 2025 and the second installment, in the amount of R\$ 6.0 million (R\$ 0.04055444989 per share) was paid on 09/03/2025, and the third installment, in the amount of R\$ 7.8 million (R\$ 0.05253337640) was paid on January 6, 2026.

At a Board of Directors' Meeting held on October 29, 2025, the declaration of distribution of Interest on Equity accrued in the period from August to October 2025 was approved, in the gross amount of R\$ 9.5 million (R\$ 0.06474713761 per share) based on the shareholding position of November 3, 2025. The first installment, in the amount of R\$ 4.7 million (R\$ 0.03214434305 per share), was paid on January 6, 2026; the second installment, in the amount of R\$ 4.8 million (R\$ 0.03260279456 per share) was paid on May 11, 2026.

Furthermore, at a Board of Directors meeting held on December 17, 2025, the declaration of distribution of Interest on Equity ("JCP") in the total amount of R\$ 6.6 million (R\$ 0.04514632207 per share) was approved, based on the shareholding position as of November 3, 2025, and paid on May 11, 2026.

Additionally, at a Board of Directors meeting held on December 30, 2025, the declaration of distribution of Interest on Equity ("JCP") accrued in the period from 1996 to 2005 was approved, in the gross amount of R\$ 4.7 million (R\$ 0.03225465391 per share) paid on May 11, 2026, calculated based on the application of the Long-Term Interest Rate (TJLP) pro rata day on the Company's Net Worth on December 31 of each fiscal year, with imputation to the mandatory dividend provided for in article 38 of the Bylaws, pursuant to article 9 of Law No. 9,249/1995 and CVM Resolution No. 143/2022. The aforementioned decision observes the understanding established by the Supreme Federal Court in Topic 1319, which recognized the possibility of deducting, for tax purposes, interest on equity related to previous fiscal years, provided that it was calculated in accordance with the legislation in force at the time and declared in accordance with the applicable legal criteria, thus providing legal certainty to the approved distribution.

Share buyback program: On June 9, 2026, the Company announced that its Board of Directors had approved the 6th Share Buyback Program, covering the acquisition of up to 4,500,000 common shares, representing approximately 9.4% of the Company's outstanding shares at that time, with a maximum term of 12 months.

In the first half of 2026 (1H26), the Company repurchased shares totaling R\$ 16.1 million, taking into account shares repurchased under both the 5th and 6th Share Buyback Programs. As of the end of July 2026, the Company held 1,217,442 shares in treasury.

Furthermore, also on June 9, 2026, the Company announced the cancellation of 4,455,436 common shares held in treasury—which had been acquired under the Company's 5th share buyback program—without a reduction in share capital. This cancellation was carried out specifically for the purposes of Articles 9 and 10 of CVM Resolution No. 77, dated March 29, 2022 ("CVM Resolution No. 77/22"), and was charged against available profit reserve balances, excluding the reserve balances specified in Article 8, Paragraph 1, Item I of CVM Resolution No. 77/22.

Increase in Share Capital with Share Bonus: At a Board of Directors' Meeting (RCA) held on December 30, 2025, Vittia S.A. approved an increase in its share capital through the capitalization of R\$ 137.1 million recorded in profit reserves in the balance sheet as of December 31, 2024, with the resulting bonus share distribution to shareholders. As a result of this transaction, 14,731,402 new common shares were issued and granted free of charge at a ratio of 10% (10 new shares for every 100 shares held), based on the shareholder position as of April 9, 2026. The bonus shares were credited to shareholders on April 13, 2026 and will carry the same rights as the existing shares, including full entitlement to dividends and/or interest on shareholders' equity declared with a record date after April 14, 2026. As a result, and considering the cancellation of shares mentioned in the section above, the Company's share capital is now divided into 157,589,984 shares.

Income Statement for the Year – 2Q26 vs. 2Q25 and 1H26 vs. 1H25

Income Statement (R\$ thousand)	2Q26	2Q25	Chg. %	1H26	1H25	Chg. %
Net revenue	114,048	99,060	15.1%	235,962	236,880	(0.4%)
Sales costs	(96,414)	(84,928)	13.5%	(183,112)	(180,707)	1.3%
Gross profit	17,634	14,132	24.8%	52,850	56,173	(5.9%)
Gross margin	15.5%	14.3%	+1.2 p.p.	22.4%	23.7%	-1.3 p.p.
Selling expenses	(14,786)	(15,244)	(3.0%)	(32,555)	(32,952)	(1.2%)
Provision for expected credit losses	(57)	(91)	(37.4%)	64	782	(91.8%)
General and administrative expenses	(30,491)	(29,185)	4.5%	(60,720)	(56,953)	6.6%
Other net operating income (expenses)	1,721	579	197.2%	2,262	266	750.4%
SG&A expenses	(43,613)	(43,941)	(0.7%)	(90,949)	(88,857)	2.4%
Operating profit	(25,979)	(29,809)	(12.8%)	(38,099)	(32,684)	16.6%
Financial income	10,514	13,134	(19.9%)	23,147	26,565	(12.9%)
Financial expenses	(10,800)	(14,946)	(27.7%)	(21,321)	(27,869)	(23.5%)
Financial result	(286)	(1,812)	(84.2%)	1,826	(1,304)	N/A
Profit (loss) before income tax and social contribution	(26,265)	(31,620)	(16.9%)	(36,273)	(33,988)	6.7%
Current and Deferred Income Tax and Social Contribution	8,350	10,438	(20.0%)	11,876	10,847	9.5%
Result for the period	(17,915)	(21,182)	(15.4%)	(24,397)	(23,141)	5.4%
Net margin	(15.7%)	(21.4%)	+5.7 p.p.	(10.3%)	(9.8%)	-0.5 p.p.

Cash Flow Statements – 1H26 vs. 1H25

In thousands of R\$, except %	1H26	1H25
Cash Flow from Operating Activities		
Result for the period	(24,397)	(23,141)
Adjustments for:		
Depreciation and amortization	12,038	12,327
Residual cost of sold/written-off fixed assets	680	1,286
Current taxes	400	820
Deferred taxes	(12,276)	(11,667)
Provision for bônus	6,568	6,743
Provision for commissions	1,500	3,697
Interest and monetary variations on loans and financing	14,000	5,804
Interest on lease liabilities	1,213	1,523
Present value adjustment variation	(6,462)	(6,556)
Provision for doubtful accounts	(64)	(782)
Fair value of derivate financial instruments	(1,250)	12,353
Provision for contingencies	115	284
Exchange Variation	3,744	(8,637)
Change in working capital		
Increase (decrease) in trade receivables	145,302	162,496
Increase (decrease) in inventories	(59,340)	(100,494)
Increase (decrease) in taxes recoverable	7,406	3,760
Increase (decrease) in other receivables	(474)	1,809
Increase (decrease) in suppliers	8,336	7,454
Increase (decrease) in payroll and social security charges	(341)	(1,821)
Increase (decrease) in taxes and contributions payable	(1,736)	(2,324)
Increase (decrease) in advances from customers	19,603	25,845
Increase (decrease) in other accounts payable	(2,933)	(3,623)
Cash generated by Operations	111,631	87,156
Income tax and social contribution paid	(635)	(890)
Interest paid on lease liabilities	(1,213)	(1,523)
Interest paid on loans and financing	(7,199)	(12,668)
Net cash from operating activities	102,585	72,075

Cash Flow Statements – 1H26 vs. 1H25 (continued)
Cash flows from investing activities

Receivables from the sale of fixed assets	1,020	1,348
Acquisition of fixed assets	(15,222)	(15,008)
Increase in intangible assets	(118)	38
Net cash flow used in investing activities	(14,320)	(13,622)

Cash flows from financing activities

Loans and financing raised	65,000	68,000
Payment of lease liabilities	(3,588)	(3,337)
Payment of loans and financing	(46,824)	(81,824)
Realized derivative financial instruments	(3,384)	-
Acquisition of treasury shares	(16,082)	(9,958)
Dividends paid	(25,481)	(22,200)
Net cash flows generated by financing activities	(30,359)	(49,319)

Increase (decrease) in cash and cash equivalents, net	57,905	9,134
Cash and cash equivalents at the beginning of the period	47,963	54,473
Cash and cash equivalents at the end of the period	105,868	63,607

Balance Sheet as of June 30, 2026 and December 31, 2025

In thousands of R\$, except %	1H26	2025
Assets		
Current assets	542,181	575,949
Cash and cash equivalents	105,868	47,963
Derivative Financial Instruments – Assets	975	-
Trade receivables	186,328	327,881
Inventories	217,130	157,790
Taxes recoverable	26,121	33,625
Current tax asset	1,648	5,026
Other receivables	4,111	3,664
Non-current assets	376,504	360,040
Non-current receivables	34,070	20,800
Trade receivables	4,770	1,993
Taxes recoverable	3,721	3,624
Deferred tax asset	19,967	13,732
Current tax asset	4,134	-
Judicial deposits	1,478	1,451
Permanent	342,434	339,240
Investments	255	255
Fixed assets	308,196	302,120
Right of use	20,332	23,096
Intangible assets	13,651	13,769
Total assets	918,685	935,989
Liabilities and equity		
Current liabilities	249,711	217,187
Suppliers	22,533	14,197
Loans and financing	155,474	124,930
Derivative Financial Instruments	17	2,784
Payroll and social security charges	27,253	20,753
Taxes and contributions payable	1,804	3,540
Current tax liabilities	231	781
Advances from customers	26,285	6,682
Dividends to distribute and interest on equity	-	25,481
Lease liability	6,466	6,956
Other accounts payable	9,648	11,083
Non-current liabilities	64,805	74,429
Loans and financing	46,804	48,627
Provision for risks	850	735
Deferred tax liability	-	6,043
Lease liability	17,151	19,024
Total equity attributable to controlling shareholders	604,492	644,605
Non-controlling interests	(323)	(232)
Total equity	604,169	644,373
Total liabilities	314,516	291,616
Total liabilities and equity	918,685	935,989



Investor Relations

Alexandre Del Nero Frizzo – CFO and IRO

Laís Nunes – IR Specialist



ri@vittia.com.br



ri.vittia.com.br